SPRIM Global Investments and OneIM Forge New Venture to Boost Clinical Trials Funding

SPRIM Global Investments and OneIM Join Forces for Clinical Trials Funding

On March 11, 2025, SPRIM Global Investments (SGI), a prominent global investment firm focused on life sciences and clinical phase pharmaceutical services, announced a strategic partnership with One Investment Management (OneIM) to establish a joint venture worth $300 million aimed at accelerating funding for clinical trials.

This new collaboration is set to enhance SGI’s innovative financing platform, TrialCap, which provides essential funding solutions designed to support clinical studies from Phase 1 through 3. With SGI’s extensive industry experience, TrialCap aims to offer flexible financial support to biotech and medtech companies, therefore expediting the development and market introduction of groundbreaking therapies.

Michael Shleifer, co-founder and managing partner at SPRIM Global Investments, stated, "Our mission is to eliminate the financial barriers that hinder biotech and medtech companies’ focus on research and development. Through this strategic partnership with OneIM, we are expanding our capacity to offer critical funding solutions that drive innovation in the life sciences sector."

Echoing this sentiment, Matt Ross, a partner at OneIM, expressed excitement about the immense potential in the life sciences sector. He highlighted the importance of collaborating with SGI, a company with a proven track record, excellent healthcare connections, and a robust opportunity pipeline. Ross particularly looked forward to accelerating the growth of the TrialCap platform alongside SGI’s team.

About SPRIM Global Investments

Founded in 2008, SPRIM Global Investments specializes in life sciences in the clinical phase and pharmaceutical services. The firm's innovative investment approach enables flexible and impactful financing options for biotech companies globally, thereby supporting clinical trials and facilitating the development of transformative therapies. More information can be found at www.sprim.net.

About OneIM

OneIM is a global alternative investment manager that invests across various asset classes, industries, and regions, employing a flexible investment strategy aimed at creating lasting value in partnership with exceptional partners and management teams. Established in 2022, OneIM focuses on situations where it can leverage its cross-asset expertise and capital base to deliver differentiated risk-adjusted returns. The firm currently manages approximately $7 billion in assets and operates from offices in Abu Dhabi, London, Tokyo, and New York. For further details, visit www.oneimgroup.com.

This collaboration between SPRIM and OneIM marks a significant advancement in funding strategies for the life sciences field, promising to accelerate the development of crucial medical innovations aimed at improving healthcare outcomes worldwide.